$27.9
1.4%
Downside
Day's Volatility :3.76%
Upside
2.4%
40.72%
Downside
52 Weeks Volatility :43.2%
Upside
4.19%
Period | Anika Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 10.72% | 6.5% | 0.0% |
6 Months | 16.02% | 7.1% | 0.0% |
1 Year | 13.24% | 9.8% | 0.0% |
3 Years | -30.49% | 14.2% | -20.2% |
Market Capitalization | 413.0M |
Book Value | $14.07 |
Earnings Per Share (EPS) | -5.28 |
PEG Ratio | 2.23 |
Wall Street Target Price | 31.0 |
Profit Margin | -45.39% |
Operating Margin TTM | -23.67% |
Return On Assets TTM | -1.81% |
Return On Equity TTM | -31.61% |
Revenue TTM | 169.3M |
Revenue Per Share TTM | 11.54 |
Quarterly Revenue Growth YOY | 6.9% |
Gross Profit TTM | 96.8M |
EBITDA | 4.0M |
Diluted Eps TTM | -5.28 |
Quarterly Earnings Growth YOY | -0.5 |
EPS Estimate Current Year | -0.11 |
EPS Estimate Next Year | 0.58 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | 0.06 |
What analysts predicted
Upside of 11.11%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 105.6M | ↓ 6.93% |
Net Income | 18.7M | ↓ 41.16% |
Net Profit Margin | 17.74% | ↓ 10.31% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 114.6M | ↑ 8.58% |
Net Income | 27.2M | ↑ 45.25% |
Net Profit Margin | 23.73% | ↑ 5.99% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 130.5M | ↑ 13.83% |
Net Income | -24.0M | ↓ 188.19% |
Net Profit Margin | -18.38% | ↓ 42.11% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 147.8M | ↑ 13.29% |
Net Income | 4.1M | ↓ 117.24% |
Net Profit Margin | 2.8% | ↑ 21.18% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 156.2M | ↑ 5.71% |
Net Income | -14.9M | ↓ 459.43% |
Net Profit Margin | -9.51% | ↓ 12.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 166.7M | ↑ 6.67% |
Net Income | -82.7M | ↑ 456.34% |
Net Profit Margin | -49.6% | ↓ 40.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 39.6M | ↓ 1.59% |
Net Income | -4.9M | ↑ 17.56% |
Net Profit Margin | -12.39% | ↓ 2.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.9M | ↓ 4.29% |
Net Income | -10.4M | ↑ 110.88% |
Net Profit Margin | -27.29% | ↓ 14.9% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.3M | ↑ 16.82% |
Net Income | -2.7M | ↓ 73.52% |
Net Profit Margin | -6.19% | ↑ 21.1% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 41.5M | ↓ 6.4% |
Net Income | -6.6M | ↑ 139.91% |
Net Profit Margin | -15.86% | ↓ 9.67% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.0M | ↑ 3.63% |
Net Income | -63.0M | ↑ 858.03% |
Net Profit Margin | -146.61% | ↓ 130.75% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 40.5M | ↓ 5.7% |
Net Income | -4.5M | ↓ 92.83% |
Net Profit Margin | -11.14% | ↑ 135.47% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 279.0M | ↓ 1.28% |
Total Liabilities | 15.4M | ↓ 19.58% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 330.7M | ↑ 18.54% |
Total Liabilities | 42.3M | ↑ 175.22% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 365.6M | ↑ 10.55% |
Total Liabilities | 93.2M | ↑ 120.18% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 347.5M | ↓ 4.94% |
Total Liabilities | 60.5M | ↓ 35.14% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 349.1M | ↑ 0.46% |
Total Liabilities | 63.6M | ↑ 5.15% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 270.6M | ↓ 22.48% |
Total Liabilities | 58.4M | ↓ 8.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 349.1M | ↑ 0.4% |
Total Liabilities | 63.6M | ↑ 1.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 339.1M | ↓ 2.88% |
Total Liabilities | 61.5M | ↓ 3.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.9M | ↓ 3.01% |
Total Liabilities | 54.9M | ↓ 10.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.2M | ↓ 0.22% |
Total Liabilities | 57.7M | ↑ 5.11% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 270.6M | ↓ 17.53% |
Total Liabilities | 58.4M | ↑ 1.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 263.7M | ↓ 2.55% |
Total Liabilities | 55.2M | ↓ 5.41% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 34.9M | ↓ 14.44% |
Investing Cash Flow | -50.3M | ↑ 302.7% |
Financing Cash Flow | -28.9M | ↓ 9305.1% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.0M | ↑ 5.98% |
Investing Cash Flow | 39.7M | ↓ 178.98% |
Financing Cash Flow | -8.1M | ↓ 71.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.1M | ↓ 64.69% |
Investing Cash Flow | -71.3M | ↓ 279.55% |
Financing Cash Flow | -3.8M | ↓ 53.65% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 8.4M | ↓ 35.73% |
Investing Cash Flow | -3.1M | ↓ 95.62% |
Financing Cash Flow | -6.8M | ↑ 79.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.4M | ↓ 47.49% |
Investing Cash Flow | -7.5M | ↑ 140.09% |
Financing Cash Flow | -4.9M | ↓ 28.43% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 481.0K | ↓ 82.24% |
Investing Cash Flow | -2.5M | ↑ 49.56% |
Financing Cash Flow | 667.0K | ↓ 114.47% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.6M | ↓ 852.18% |
Investing Cash Flow | -1.4M | ↓ 45.08% |
Financing Cash Flow | -1.6M | ↓ 341.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.3M | ↑ 129.22% |
Investing Cash Flow | -1.5M | ↑ 4.9% |
Financing Cash Flow | -4.9M | ↑ 206.45% |
Sell
Neutral
Buy
Anika Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Anika Therapeutics Inc | 10.37% | 16.02% | 13.24% | -30.49% | -49.31% |
![]() Intuitive Surgical, Inc. | -1.32% | 16.54% | 32.6% | 35.62% | 148.32% |
![]() Resmed Inc. | 11.69% | 9.57% | -6.0% | -19.79% | 64.22% |
![]() Becton, Dickinson And Company | 0.5% | -1.64% | -17.69% | -6.68% | -8.49% |
![]() West Pharmaceutical Services Inc | -14.37% | -23.3% | -26.95% | -26.58% | 102.44% |
![]() Alcon Ag | 2.41% | 20.84% | 8.21% | 30.7% | 54.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Anika Therapeutics Inc | NA | NA | 2.23 | -0.11 | -0.32 | -0.02 | NA | 14.07 |
![]() Intuitive Surgical, Inc. | 78.14 | 78.14 | 7.13 | 6.63 | 0.16 | 0.08 | NA | 41.4 |
![]() Resmed Inc. | 32.24 | 32.24 | 1.75 | 7.73 | 0.22 | 0.12 | 0.01 | 31.52 |
![]() Becton, Dickinson And Company | 50.71 | 50.71 | 1.34 | 13.04 | 0.05 | 0.03 | 0.02 | 88.74 |
![]() West Pharmaceutical Services Inc | 42.71 | 42.71 | 6.72 | 7.74 | 0.21 | 0.11 | 0.0 | 36.72 |
![]() Alcon Ag | 44.05 | 44.05 | 4.59 | 3.07 | 0.05 | 0.02 | 0.0 | 42.13 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Anika Therapeutics Inc | Buy | $413.0M | -49.31% | NA | -45.39% |
![]() Intuitive Surgical, Inc. | Buy | $161.3B | 148.32% | 78.14 | 27.65% |
![]() Resmed Inc. | Buy | $30.8B | 64.22% | 32.24 | 20.91% |
![]() Becton, Dickinson And Company | Buy | $68.6B | -8.49% | 50.71 | 6.76% |
![]() West Pharmaceutical Services Inc | Buy | $23.7B | 102.44% | 42.71 | 19.42% |
![]() Alcon Ag | Buy | $45.8B | 54.72% | 44.05 | 10.96% |
Insights on Anika Therapeutics Inc
Revenue is down for the last 2 quarters, 42.97M → 40.52M (in $), with an average decrease of 5.7% per quarter
Netprofit is up for the last 2 quarters, -63.0M → -4.51M (in $), with an average increase of 1295.7% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 32.6% return, outperforming this stock by 19.4%
In the last 3 years, Intuitive Surgical, Inc. has given 35.6% return, outperforming this stock by 66.1%
Trigran Investments Inc
BlackRock Inc
Caligan Partners LP
Dimensional Fund Advisors, Inc.
Vanguard Group Inc
Morgan Stanley - Brokerage Accounts
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Organization | Anika Therapeutics Inc |
Employees | 357 |
CEO | Dr. Cheryl Renee Blanchard Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$27.90
-1.45%
Keyarch Acquisition Corp
$27.90
-1.45%
Connexa Sports Technologies Inc
$27.90
-1.45%
Us Value Etf
$27.90
-1.45%
First Wave Biopharma Inc
$27.90
-1.45%
Global X Msci Next Emerging
$27.90
-1.45%
Fat Projects Acquisition Corp
$27.90
-1.45%
Capital Link Global Fintech
$27.90
-1.45%
Applied Uv Inc
$27.90
-1.45%